USV Launches Xenia Brand Range Following Empagliflozin Patent Expiry

New Delhi: Strengthening its leadership in diabetes care, USV Pvt. Ltd. has announced the launch of its Xenia brand range, following the recent patent expiry of Empagliflozin in India. Xenia offers a comprehensive set of products designed for the effective management of Type 2 Diabetes Mellitus (T2DM), heart failure, and chronic kidney disease.

The Xenia brand range will come in a variety of portfolio options, including monotherapy and fixed-dose combinations to cater to diverse patient needs. The lineup includes formulations of Empagliflozin alone, as well as combinations with Metformin and Sitagliptin, offering flexible treatment choices for clinicians and patients alike.

The Xenia portfolio comprises five key products designed to address varied treatment needs. It includes Xenia 10, containing Empagliflozin 10 mg, and Xenia 25, containing Empagliflozin 25 mg as monotherapy options. Additionally, the range offers Xenia M 12.5/500, combining Empagliflozin 12.5 mg with Metformin 500 mg, and Xenia M 12.5/1000 ER, which pairs Empagliflozin 12.5 mg with Metformin 1000 mg in an extended-release form. The brand range also includes Xenia ST 25, a fixed dose combination of Empagliflozin 25 mg with Sitagliptin 100 mg.

The Xenia range has been introduced across different price points. Xenia 10 is priced at ₹125 per pack, Xenia 25 at ₹163.9, Xenia M 12.5/500 at ₹140, Xenia M 12.5/1000 ER at ₹165, and Xenia ST 25 at ₹220.2.

Commenting on the launch, Prashant Tewari, Managing Director, USV said, “India has over 101 million people with Type 2 diabetes and 136 million with prediabetes. With Xenia, we aim to expand access to modern diabetes care.”

With the loss of exclusivity, Empagliflozin and its combinations are now available at significantly reduced prices, enhancing affordability. USV’s extensive reach across metros, Tier I, II & III cities, corporate hospitals, and e-pharmacies ensures Xenia's accessibility nationwide, including rural areas.